ADT in prostate ca increases risk of bone and heart complications
Prostate cancer patients who undergo androgen deprivation therapy have an increased chance of developing bone- and heart-related side effects compared to patients who do not undergo ADT, according to an analysis in Cancer online (April 29, 2009).
Prostate cancer patients who undergo androgen deprivation therapy have an increased chance of developing bone- and heart-related side effects compared to patients who do not undergo ADT, according to an analysis in Cancer online (April 29, 2009).
Researchers from the University of Texas Health Sciences Center in Houston found that men treated with ADT had an increased risk of bone fractures and heart-related death, although the absolute risk for both was still low.
For bone fractures, there was a 23% increased risk compared to prostate cancer patients who did not undergo ADT.
The absolute risk of fracture among ADT-exposed men was 7.2 per 100 person years.
For heart-related death, the increased risk among ADT-exposed men was 17% higher compared to other prostate cancer patients. However, because the baseline risk is low, the increase translated to an additional one-to-two deaths per 1,000 men who received ADT. Lead author Lockwood G. Taylor, MPH, and colleagues also noted a link between ADT and diabetes.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
